KR20240155234A - 인간 암 치료에서의 경구용 pclx-001 - Google Patents

인간 암 치료에서의 경구용 pclx-001 Download PDF

Info

Publication number
KR20240155234A
KR20240155234A KR1020247029643A KR20247029643A KR20240155234A KR 20240155234 A KR20240155234 A KR 20240155234A KR 1020247029643 A KR1020247029643 A KR 1020247029643A KR 20247029643 A KR20247029643 A KR 20247029643A KR 20240155234 A KR20240155234 A KR 20240155234A
Authority
KR
South Korea
Prior art keywords
pclx
cancer
hours
per day
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029643A
Other languages
English (en)
Korean (ko)
Inventor
존 로버트 맥키
닐 메이너드 데이비스
Original Assignee
페이실렉스 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페이실렉스 파마슈티컬스 인코포레이티드 filed Critical 페이실렉스 파마슈티컬스 인코포레이티드
Publication of KR20240155234A publication Critical patent/KR20240155234A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247029643A 2022-03-03 2023-03-03 인간 암 치료에서의 경구용 pclx-001 Pending KR20240155234A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316153P 2022-03-03 2022-03-03
US63/316,153 2022-03-03
PCT/CA2023/050281 WO2023164776A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Publications (1)

Publication Number Publication Date
KR20240155234A true KR20240155234A (ko) 2024-10-28

Family

ID=87882761

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029643A Pending KR20240155234A (ko) 2022-03-03 2023-03-03 인간 암 치료에서의 경구용 pclx-001

Country Status (10)

Country Link
US (1) US20250161299A1 (https=)
EP (1) EP4486344A4 (https=)
JP (1) JP2025507923A (https=)
KR (1) KR20240155234A (https=)
CN (1) CN118829428A (https=)
AU (1) AU2023228703A1 (https=)
CA (1) CA3244234A1 (https=)
IL (1) IL314984A (https=)
MX (1) MX2024010584A (https=)
WO (1) WO2023164776A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
JP7539760B2 (ja) * 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング
GB201820660D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
MX2023004341A (es) * 2020-10-20 2023-05-24 Pacylex Pharmaceuticals Inc Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.

Also Published As

Publication number Publication date
JP2025507923A (ja) 2025-03-21
CN118829428A (zh) 2024-10-22
WO2023164776A1 (en) 2023-09-07
MX2024010584A (es) 2024-09-06
AU2023228703A1 (en) 2024-09-12
CA3244234A1 (en) 2023-09-07
EP4486344A4 (en) 2026-03-04
IL314984A (en) 2024-10-01
EP4486344A1 (en) 2025-01-08
US20250161299A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
Verweij et al. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
WO2017013160A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR20180022926A (ko) 암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
KR20240155234A (ko) 인간 암 치료에서의 경구용 pclx-001
US12011434B2 (en) Treatments with nirogacestat
JP2018505224A (ja) ナノ粒子を含む組成物並びに腫瘍を治療する方法
EP3405203A1 (en) Methods for treating cancer
JP2005508856A (ja) 血管形成を阻害する方法
JP2014515390A (ja) Ｐｉ３ｋ阻害剤化合物を用いた中皮腫の治療法
AU2018285823A1 (en) Tinostamustine for use in treating ovarian cancer
US20240066007A1 (en) Treatments with nirogacestat
CA3123510A1 (en) Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
JP2021515032A (ja) 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置
WO2015153978A1 (en) Methods for the treatment of tumors
WO2025050208A1 (en) Oral pclx-001 in the treatment of human cancer
Dreicer et al. A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
US20250025446A1 (en) Treatments with nirogacestat
KR102616469B1 (ko) 혈액 순환 미세체외소체 매개 암 치료용 조성물
WO2026019787A1 (en) Methods of treating merkel cell carcinoma with tryptophan hydroxylase inhibitors
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
TW202444376A (zh) 治療癌症之方法
WO2024148437A1 (en) Use of pclx-001 or pclx-002 as a radiosensitizer
KR20240060625A (ko) 암 치료를 위한 삼중제 요법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000